PBC Approval
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081121/#:~:text=sclerosis%2C%20among%20others.-,2,1%2C3
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280809/#:~:text=Incomplete%20response%20to%20UDCA%20was,Conclusion
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218860s000lbl.pdf?utm_medium=email&utm_source=govdelivery
https://www.ipsen.com/us/press-releases/results-from-ipsens-elative-pivotal-phase-iii-trial-of-elafibranor-in-pbc-presented-as-late-breaking-data-at-aasld-congress-and-published-in-new-england-journal-of-medicine/




Skye Biosciences Update
https://ir.skyebioscience.com/news-events/press-releases/detail/197/skye-concentrates-strategy-and-clinical-development-focus
"Tuesday. June 11. Oppenheimer & Co. Inc. HEALTHCARE EQUITIES- Sales and Trading Commentary, not a Product of Oppenheimer Research. For Institutional Investors."- source available at request.

